Duloxetine 60 mg versus placebo for major depressive disorder with painful physical symptoms

Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Duloxetine with Placebo (2 arms). Primary endpoints: Mean change from baseline in BPI-SF average pain score over 8 weeks and Mean change from baseline in MADRS total score over 8 weeks. Started Oct 2009; status: completed.